You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDiflunisal
Accession NumberDB00861  (APRD00922, DB06895)
TypeSmall Molecule
GroupsApproved
DescriptionDiflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
Structure
Thumb
Synonyms
2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid
2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid
5-(2,4-Difluorophenyl)salicylic acid
Diflunisal
Diflunisal
Diflunisal
Diflunisalum
Dolobid
External Identifiers
  • MK 647
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diflunisaltablet500 mgoralAa Pharma Inc1993-12-31Not applicableCanada
Diflunisaltablet250 mgoralAa Pharma Inc1993-12-31Not applicableCanada
Diflunisal-250 - Tab 250mgtablet250 mgoralPro Doc Limitee1995-12-312000-07-31Canada
Diflunisal-500 - Tab 500mgtablet500 mgoralPro Doc Limitee1995-12-312000-07-31Canada
Dolobid Tab 250mgtablet250 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-311998-08-14Canada
Dolobid Tab 500mgtablet500 mgoralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1983-12-312000-08-03Canada
Novo-diflunisaltablet250 mgoralTeva Canada Limited1993-12-31Not applicableCanada
Novo-diflunisaltablet500 mgoralTeva Canada Limited1993-12-31Not applicableCanada
Nu-diflunisal Tab 250mgtablet250 mgoralNu Pharm Inc1994-12-312012-09-04Canada
Nu-diflunisal Tab 500mgtablet500 mgoralNu Pharm Inc1994-12-312012-09-04Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diflunisaltablet, film coated500 mg/1oralTeva Pharmaceuticals USA Inc1992-11-01Not applicableUs
Diflunisaltablet, film coated500 mg/1oralRising Pharmaceuticals Inc.2012-05-01Not applicableUs
Diflunisaltablet, film coated500 mg/1oralA S Medication Solutions Llc1992-11-01Not applicableUs
Diflunisaltablet, film coated500 mg/1oralCarilion Materials Management1992-11-01Not applicableUs
Diflunisaltablet, film coated500 mg/1oralPhysicians Total Care, Inc.2009-07-21Not applicableUs
Diflunisaltablet, film coated500 mg/1oralPd Rx Pharmaceuticals, Inc.2010-08-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AntonEverest
DolobidMerck
Brand mixturesNot Available
SaltsNot Available
Categories
UNII7C546U4DEN
CAS number22494-42-4
WeightAverage: 250.1976
Monoisotopic: 250.044150532
Chemical FormulaC13H8F2O3
InChI KeyInChIKey=HUPFGZXOMWLGNK-UHFFFAOYSA-N
InChI
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
IUPAC Name
5-(2,4-difluorophenyl)-2-hydroxybenzoic acid
SMILES
OC(=O)C1=C(O)C=CC(=C1)C1=C(F)C=C(F)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBiphenyls and derivatives
Direct ParentBiphenyls and derivatives
Alternative Parents
Substituents
  • Biphenyl
  • Salicylic acid
  • Salicylic acid or derivatives
  • Hydroxybenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis.
PharmacodynamicsDiflunisal is a nonsteroidal drug with analgesic, anti-inflammatory and antipyretic properties. It is a peripherally-acting non-narcotic analgesic drug. Habituation, tolerance and addiction have not been reported. Diflunisal is a difluorophenyl derivative of salicylic acid. Chemically, diflunisal differs from aspirin (acetylsalicylic acid) in two respects. The first of these two is the presence of a difluorophenyl substituent at carbon 1. The second difference is the removal of the 0-acetyl group from the carbon 4 position. Diflunisal is not metabolized to salicylic acid, and the fluorine atoms are not displaced from the difluorophenyl ring structure.
Mechanism of actionThe precise mechanism of the analgesic and anti-inflammatory actions of diflunisal is not known. Diflunisal is a prostaglandin synthetase inhibitor. In animals, prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain. Since prostaglandins are known to be among the mediators of pain and inflammation, the mode of action of diflunisal may be due to a decrease of prostaglandins in peripheral tissues.
Related Articles
AbsorptionRapidly and completely absorbed following oral administration, with a bioavailability of 80-90%. Peak plasma concentrations are achieved 2 - 3 hours following oral administration.
Volume of distributionNot Available
Protein bindingAt least 98 to 99% of diflunisal in plasma is bound to proteins.
Metabolism

Hepatic, primarily via glucuronide conjugation (90% of administered dose).

Route of eliminationThe drug is excreted in the urine as two soluble glucuronide conjugates accounting for about 90% of the administered dose. Little or no diflunisal is excreted in the feces.
Half life8 to 12 hours
ClearanceNot Available
ToxicityOral LD50 in rat, mouse, and rabbit is 392 mg/kg, 439 mg/kg, and 603 mg/kg, respectively. Symptoms of overdose include drowsiness, nausea, vomiting, diarrhea, hyperventilation, tachycardia, sweating, tinnitus, disorientation, stupor, and coma. The lowest dose without the presence of other medicines which caused death was 15 grams.

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of diflunisal. Short-term use does not appear to be associated with increased cardiovascular risk (except when used immediately following coronary artery bypass graft (CABG) surgery). Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Severe hepatic reactions, including cholestasis and/or jaundice, have been reported. May cause rash or hypersensitivity syndrome.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Diflunisal Action PathwayDrug actionSMP00289
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9945
Blood Brain Barrier+0.8047
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.6927
P-glycoprotein inhibitor INon-inhibitor0.9407
P-glycoprotein inhibitor IINon-inhibitor0.9735
Renal organic cation transporterNon-inhibitor0.911
CYP450 2C9 substrateNon-substrate0.7982
CYP450 2D6 substrateNon-substrate0.9201
CYP450 3A4 substrateNon-substrate0.7145
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.6684
CYP450 2D6 inhibitorNon-inhibitor0.9357
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5156
Ames testNon AMES toxic0.9666
CarcinogenicityNon-carcinogens0.7828
BiodegradationNot ready biodegradable0.988
Rat acute toxicity2.7735 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.983
hERG inhibition (predictor II)Non-inhibitor0.9178
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral250 mg
Tabletoral500 mg
Tablet, film coatedoral500 mg/1
Prices
Unit descriptionCostUnit
Dolobid 60 500 mg tablet Bottle92.83USD bottle
Diflunisal 250 mg tablet1.74USD tablet
Diflunisal powder1.56USD g
Diflunisal 500 mg tablet1.46USD tablet
Apo-Diflunisal 500 mg Tablet0.75USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point210-211Ruyle, W.V., Jarett, L.H. and Matzuk, A.R. ; U S . Patent 3,714,226; January 30, 1973; assigned to Merck & Co., Inc.
water solubilityPractically insoluble (14.5 mg/L) at neutral or acidic pH.Not Available
logP4.44SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0711 mg/mLALOGPS
logP3.11ALOGPS
logP3.91ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)2.69ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity60.86 m3·mol-1ChemAxon
Polarizability22.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0fai-1690000000-d231ff5a9ac7d9769d2dView in MoNA
References
Synthesis Reference

Ruyle, W.V., Jarett, L.H. and Matzuk, A.R. ; U S . Patent 3,714,226; January 30, 1973; assigned to Merck & Co., Inc.

General ReferencesNot Available
External Links
ATC CodesN02BA11
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (94.1 KB)
MSDSDownload (73.4 KB)
Interactions
Drug Interactions
Drug
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Diflunisal is combined with 4-Androstenedione.
AbciximabDiflunisal may increase the anticoagulant activities of Abciximab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Diflunisal.
AcarboseDiflunisal may increase the hypoglycemic activities of Acarbose.
AcebutololDiflunisal may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aceclofenac.
AcenocoumarolDiflunisal may increase the anticoagulant activities of Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Diflunisal.
AlbiglutideDiflunisal may increase the hypoglycemic activities of Albiglutide.
AlclometasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alclometasone.
AldosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Aldosterone.
Alendronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.
AliskirenDiflunisal may decrease the antihypertensive activities of Aliskiren.
AlogliptinDiflunisal may increase the hypoglycemic activities of Alogliptin.
AlprenololDiflunisal may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Diflunisal.
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Diflunisal.
AlteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Alteplase.
ALX-0081The risk or severity of adverse effects can be increased when Diflunisal is combined with ALX-0081.
AmcinonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Amcinonide.
AmikacinDiflunisal may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideDiflunisal may decrease the antihypertensive activities of Amiloride.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Diflunisal.
Ammonium chlorideThe serum concentration of Diflunisal can be increased when it is combined with Ammonium chloride.
AnagrelideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anagrelide.
AncrodDiflunisal may increase the anticoagulant activities of Ancrod.
AnistreplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Anistreplase.
AntipyrineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Antipyrine.
Antithrombin III humanDiflunisal may increase the anticoagulant activities of Antithrombin III human.
ApixabanDiflunisal may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Apremilast.
ArdeparinDiflunisal may increase the anticoagulant activities of Ardeparin.
ArgatrobanDiflunisal may increase the anticoagulant activities of Argatroban.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Diflunisal.
ArotinololDiflunisal may decrease the antihypertensive activities of Arotinolol.
AstaxanthinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Astaxanthin.
AtenololDiflunisal may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diflunisal.
BalsalazideDiflunisal may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Diflunisal.
BatroxobinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Batroxobin.
BecaplerminDiflunisal may increase the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beclomethasone dipropionate.
BefunololDiflunisal may decrease the antihypertensive activities of Befunolol.
BemiparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bemiparin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Diflunisal.
BenazeprilDiflunisal may decrease the antihypertensive activities of Benazepril.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Diflunisal.
BenoxaprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Benoxaprofen.
BeraprostThe risk or severity of adverse effects can be increased when Diflunisal is combined with Beraprost.
BetamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betamethasone.
BetaxololDiflunisal may decrease the antihypertensive activities of Betaxolol.
BevantololDiflunisal may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Diflunisal.
BisoprololDiflunisal may decrease the antihypertensive activities of Bisoprolol.
BivalirudinDiflunisal may increase the anticoagulant activities of Bivalirudin.
BopindololDiflunisal may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Bromfenac.
BromocriptineDiflunisal may increase the hypoglycemic activities of Bromocriptine.
BudesonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.
BufuralolDiflunisal may decrease the antihypertensive activities of Bufuralol.
BumetanideDiflunisal may decrease the diuretic activities of Bumetanide.
BupranololDiflunisal may decrease the antihypertensive activities of Bupranolol.
CanagliflozinDiflunisal may increase the hypoglycemic activities of Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Diflunisal.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Diflunisal.
CandoxatrilDiflunisal may decrease the antihypertensive activities of Candoxatril.
CangrelorThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cangrelor.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Diflunisal.
CaptoprilDiflunisal may decrease the antihypertensive activities of Captopril.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Diflunisal.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Diflunisal.
CarteololDiflunisal may decrease the antihypertensive activities of Carteolol.
CarvedilolDiflunisal may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Diflunisal.
CeliprololDiflunisal may decrease the antihypertensive activities of Celiprolol.
CertoparinDiflunisal may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Diflunisal.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.
ChlorpropamideDiflunisal may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Diflunisal.
CholestyramineCholestyramine can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ciclesonide.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Diflunisal.
CilazaprilDiflunisal may decrease the antihypertensive activities of Cilazapril.
CilostazolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cilostazol.
Citric AcidDiflunisal may increase the anticoagulant activities of Citric Acid.
Clobetasol propionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clobetasol propionate.
ClocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clocortolone.
ClodronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clonixin.
ClopidogrelThe risk or severity of adverse effects can be increased when Diflunisal is combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Diflunisal.
ColesevelamColesevelam can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Diflunisal resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Cortisone acetate.
CyclosporineDiflunisal may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Diflunisal is combined with D-Limonene.
Dabigatran etexilateDiflunisal may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinDiflunisal may increase the anticoagulant activities of Dalteparin.
DanaparoidDiflunisal may increase the anticoagulant activities of Danaparoid.
DapagliflozinDiflunisal may increase the hypoglycemic activities of Dapagliflozin.
DaunorubicinDiflunisal may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deferasirox.
DefibrotideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Defibrotide.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dehydroepiandrosterone.
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Diflunisal is combined with dehydroepiandrosterone sulfate.
DesirudinDiflunisal may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.
DesmoteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desmoteplase.
DesoximetasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoximetasone.
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Desoxycorticosterone acetate.
DexamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone.
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexamethasone isonicotinate.
DexketoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dexketoprofen.
DextranDiflunisal may increase the anticoagulant activities of Dextran.
Dextran 40Diflunisal may increase the anticoagulant activities of Dextran 40.
Dextran 70Diflunisal may increase the anticoagulant activities of Dextran 70.
Dextran 75Diflunisal may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Diflunisal.
DiclofenamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diclofenamide.
DicoumarolDiflunisal may increase the anticoagulant activities of Dicoumarol.
DiflorasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Diflorasone.
DifluocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluocortolone.
DifluprednateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluprednate.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Diflunisal.
DihydrostreptomycinDiflunisal may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Diflunisal.
DipyridamoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Dipyridamole.
DisopyramideDiflunisal may increase the hypoglycemic activities of Disopyramide.
DitazoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ditazole.
DoxorubicinDiflunisal may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneDiflunisal may increase the hyperkalemic activities of Drospirenone.
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Diflunisal is combined with Drotrecogin alfa.
DroxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Droxicam.
DulaglutideDiflunisal may increase the hypoglycemic activities of Dulaglutide.
Edetic AcidDiflunisal may increase the anticoagulant activities of Edetic Acid.
EdoxabanDiflunisal may increase the anticoagulant activities of Edoxaban.
EmpagliflozinDiflunisal may increase the hypoglycemic activities of Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Diflunisal.
EnalaprilDiflunisal may decrease the antihypertensive activities of Enalapril.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Diflunisal.
EnalaprilatDiflunisal may decrease the antihypertensive activities of Enalaprilat.
EnoxaparinDiflunisal may increase the anticoagulant activities of Enoxaparin.
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Diflunisal.
EpirizoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Epirizole.
EpirubicinDiflunisal may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneDiflunisal may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diflunisal.
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Diflunisal.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Diflunisal.
EptifibatideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Eptifibatide.
EquileninThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilenin.
EquilinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Equilin.
EsmololDiflunisal may decrease the antihypertensive activities of Esmolol.
EstroneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone.
Etacrynic acidDiflunisal may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Diflunisal.
EthoxzolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ethoxzolamide.
Ethyl biscoumacetateDiflunisal may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Diflunisal.
EtofenamateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Diflunisal is combined with Evening primrose oil.
ExenatideDiflunisal may increase the hypoglycemic activities of Exenatide.
exisulindThe risk or severity of adverse effects can be increased when Diflunisal is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Diflunisal.
FibrinolysinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fibrinolysin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Diflunisal.
FludrocortisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fludrocortisone.
FlumethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flumethasone.
FlunisolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunisolide.
FlunixinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flunixin.
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinolone Acetonide.
FluocinonideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinonide.
FluocortoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocortolone.
FluorometholoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluorometholone.
FluprednideneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluprednidene.
FluprednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluprednisolone.
FlurandrenolideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Flurandrenolide.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Diflunisal.
Fluticasone furoateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone furoate.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluticasone Propionate.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Diflunisal.
Fondaparinux sodiumDiflunisal may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Diflunisal.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diflunisal.
FosinoprilDiflunisal may decrease the antihypertensive activities of Fosinopril.
FramycetinDiflunisal may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideDiflunisal may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Diflunisal.
GentamicinDiflunisal may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Diflunisal.
GliclazideDiflunisal may increase the hypoglycemic activities of Gliclazide.
GlimepirideDiflunisal may increase the hypoglycemic activities of Glimepiride.
GlipizideDiflunisal may increase the hypoglycemic activities of Glipizide.
GlyburideDiflunisal may increase the hypoglycemic activities of Glyburide.
HaloperidolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.
HeparinDiflunisal may increase the anticoagulant activities of Heparin.
HirulogDiflunisal may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Diflunisal is combined with HMPL-004.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflunisal.
HydralazineDiflunisal may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Diflunisal.
HydrocortisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diflunisal.
Hygromycin BDiflunisal may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Diflunisal.
IbuprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Diflunisal is combined with Icatibant.
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Diflunisal.
IdarubicinDiflunisal may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Diflunisal.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Diflunisal.
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Diflunisal.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Diflunisal.
IndenololDiflunisal may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Diflunisal.
IndoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Indoprofen.
Insulin AspartDiflunisal may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirDiflunisal may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineDiflunisal may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineDiflunisal may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanDiflunisal may increase the hypoglycemic activities of Insulin Human.
Insulin LisproDiflunisal may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.
IsoxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Isoxicam.
KanamycinDiflunisal may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Diflunisal.
LabetalolDiflunisal may decrease the antihypertensive activities of Labetalol.
LanreotideDiflunisal may increase the hypoglycemic activities of Lanreotide.
LeflunomideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Leflunomide.
LepirudinDiflunisal may increase the anticoagulant activities of Lepirudin.
LevobunololDiflunisal may decrease the antihypertensive activities of Levobunolol.
LiraglutideDiflunisal may increase the hypoglycemic activities of Liraglutide.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Diflunisal.
LisinoprilDiflunisal may decrease the antihypertensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Diflunisal.
LornoxicamThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Diflunisal.
LoxoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Diflunisal.
LumiracoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Diflunisal.
MecaserminDiflunisal may increase the hypoglycemic activities of Mecasermin.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.
MedrysoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Medrysone.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Diflunisal.
MelengestrolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Melengestrol.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Diflunisal.
MesalazineDiflunisal may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Diflunisal.
MetamizoleThe risk or severity of adverse effects can be increased when Diflunisal is combined with Metamizole.
MetforminDiflunisal may increase the hypoglycemic activities of Metformin.
MethazolamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methazolamide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Diflunisal.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Diflunisal.
MethylprednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Methylprednisolone.
MetipranololDiflunisal may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.
MetoprololDiflunisal may decrease the antihypertensive activities of Metoprolol.
MetrizamideDiflunisal may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneDiflunisal may increase the hypoglycemic activities of Mifepristone.
MiglitolDiflunisal may increase the hypoglycemic activities of Miglitol.
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Diflunisal.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Diflunisal.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Diflunisal.
MoexiprilDiflunisal may decrease the antihypertensive activities of Moexipril.
MometasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mometasone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Diflunisal.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflunisal.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Diflunisal.
NadololDiflunisal may decrease the antihypertensive activities of Nadolol.
NadroparinDiflunisal may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Diflunisal.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Diflunisal.
NateglinideDiflunisal may increase the hypoglycemic activities of Nateglinide.
NCX 4016The risk or severity of adverse effects can be increased when Diflunisal is combined with NCX 4016.
NeomycinDiflunisal may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nepafenac.
NetilmicinDiflunisal may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Nimesulide.
OctreotideDiflunisal may increase the hypoglycemic activities of Octreotide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Diflunisal.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.
OlsalazineDiflunisal may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diflunisal.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Diflunisal.
OmapatrilatDiflunisal may decrease the antihypertensive activities of Omapatrilat.
OrgoteinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Orgotein.
OtamixabanDiflunisal may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.
OxprenololDiflunisal may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pamidronate.
ParamethasoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Paramethasone.
ParecoxibThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parecoxib.
ParnaparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parnaparin.
ParomomycinDiflunisal may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PasireotideDiflunisal may increase the hypoglycemic activities of Pasireotide.
PenbutololDiflunisal may decrease the antihypertensive activities of Penbutolol.
PentamidineDiflunisal may increase the hypoglycemic activities of Pentamidine.
Pentosan PolysulfateDiflunisal may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Diflunisal.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Diflunisal.
PerindoprilDiflunisal may decrease the antihypertensive activities of Perindopril.
PhenindioneDiflunisal may increase the anticoagulant activities of Phenindione.
PhenprocoumonDiflunisal may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Diflunisal.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Diflunisal.
PindololDiflunisal may decrease the antihypertensive activities of Pindolol.
PioglitazoneDiflunisal may increase the hypoglycemic activities of Pioglitazone.
PiretanideDiflunisal may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Diflunisal.
PlasminThe risk or severity of adverse effects can be increased when Diflunisal is combined with Plasmin.
PlicamycinDiflunisal may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Diflunisal.
PractololDiflunisal may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Diflunisal.
PramlintideDiflunisal may increase the hypoglycemic activities of Pramlintide.
PrasugrelThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prasugrel.
PrednicarbateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednicarbate.
PrednisoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.
PrednisoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisone.
PregnenoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pregnenolone.
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Diflunisal.
ProbenecidThe serum concentration of Diflunisal can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Propacetamol.
PropranololDiflunisal may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Diflunisal.
Protein CDiflunisal may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeDiflunisal may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Diflunisal is combined with PTC299.
PuromycinDiflunisal may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Diflunisal.
QuinaprilDiflunisal may decrease the antihypertensive activities of Quinapril.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Diflunisal.
QuinineDiflunisal may increase the hypoglycemic activities of Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Diflunisal.
RamiprilDiflunisal may decrease the antihypertensive activities of Ramipril.
RepaglinideDiflunisal may increase the hypoglycemic activities of Repaglinide.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Diflunisal.
RescinnamineDiflunisal may decrease the antihypertensive activities of Rescinnamine.
ResveratrolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Resveratrol.
ReteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Reteplase.
ReviparinDiflunisal may increase the anticoagulant activities of Reviparin.
RibostamycinDiflunisal may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Diflunisal.
RimexoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rimexolone.
RisedronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Risedronate.
RivaroxabanDiflunisal may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Diflunisal.
RosiglitazoneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Diflunisal.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Diflunisal.
SaxagliptinDiflunisal may increase the hypoglycemic activities of Saxagliptin.
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Diflunisal.
SelexipagThe risk or severity of adverse effects can be increased when Diflunisal is combined with Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Seratrodast.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diflunisal.
SitagliptinDiflunisal may increase the hypoglycemic activities of Sitagliptin.
SotalolDiflunisal may decrease the antihypertensive activities of Sotalol.
SpectinomycinDiflunisal may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Diflunisal.
SpiraprilDiflunisal may decrease the antihypertensive activities of Spirapril.
SpironolactoneDiflunisal may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Diflunisal is combined with SRT501.
StreptokinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Streptokinase.
StreptomycinDiflunisal may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinDiflunisal may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineDiflunisal may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleDiflunisal may increase the hypoglycemic activities of Sulfamethoxazole.
SulfasalazineDiflunisal may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diflunisal.
SulfisoxazoleDiflunisal may increase the hypoglycemic activities of Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Diflunisal.
SulodexideDiflunisal may increase the anticoagulant activities of Sulodexide.
SunitinibDiflunisal may increase the hypoglycemic activities of Sunitinib.
SuprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Suprofen.
TacrolimusDiflunisal may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Diflunisal.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Diflunisal.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Diflunisal.
TemocaprilDiflunisal may decrease the antihypertensive activities of Temocapril.
TenecteplaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Diflunisal.
TepoxalinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Diflunisal is combined with Teriflunomide.
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Diflunisal.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiaprofenic acid.
TicagrelorThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticagrelor.
TiclopidineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tiludronate.
TimololDiflunisal may decrease the antihypertensive activities of Timolol.
TinzaparinThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tinzaparin.
TirofibanThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tirofiban.
TixocortolThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tixocortol.
TobramycinDiflunisal may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolazamideDiflunisal may increase the hypoglycemic activities of Tolazamide.
TolbutamideDiflunisal may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Diflunisal.
TorasemideDiflunisal may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Diflunisal.
TrandolaprilDiflunisal may decrease the antihypertensive activities of Trandolapril.
TranilastThe risk or severity of adverse effects can be increased when Diflunisal is combined with Tranilast.
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Diflunisal.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Diflunisal.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Diflunisal.
TriamcinoloneThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triamcinolone.
TriamtereneDiflunisal may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Diflunisal.
TriflusalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Triflusal.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Diflunisal is combined with Trisalicylate-choline.
UrokinaseThe risk or severity of adverse effects can be increased when Diflunisal is combined with Urokinase.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Diflunisal.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Diflunisal.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Diflunisal.
VorapaxarThe risk or severity of adverse effects can be increased when Diflunisal is combined with Vorapaxar.
WarfarinDiflunisal may increase the anticoagulant activities of Warfarin.
XimelagatranDiflunisal may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Diflunisal.
Zoledronic acidThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Diflunisal is combined with Zomepirac.
Food Interactions
  • Avoid alcohol.
  • Food slightly delays rate of absorption with no effect on extent of absorption.
  • Take with food to reduce gastric irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56. [PubMed:12852483 ]
  2. Jeske AH: COX-2 inhibitors and dental pain control. J Gt Houst Dent Soc. 1999 Nov;71(4):39-40. [PubMed:10825891 ]
  3. Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35. [PubMed:11673972 ]
  4. Moore PA, Hersh EV: Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. [PubMed:11315375 ]
  5. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53. [PubMed:8737748 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Cappon GD, Cook JC, Hurtt ME: Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. Birth Defects Res B Dev Reprod Toxicol. 2003 Feb;68(1):47-56. [PubMed:12852483 ]
  2. Chen QH, Rao PN, Knaus EE: Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem. 2005 Apr 1;13(7):2459-68. [PubMed:15755648 ]
  3. Young JM, Panah S, Satchawatcharaphong C, Cheung PS: Human whole blood assays for inhibition of prostaglandin G/H synthases-1 and -2 using A23187 and lipopolysaccharide stimulation of thromboxane B2 production. Inflamm Res. 1996 May;45(5):246-53. [PubMed:8737748 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Cheng Z, Radominska-Pandya A, Tephly TR: Studies on the substrate specificity of human intestinal UDP- lucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos. 1999 Oct;27(10):1165-70. [PubMed:10497143 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Identical protein binding
Specific Function:
Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.
Gene Name:
TTR
Uniprot ID:
P02766
Molecular Weight:
15886.88 Da
References
  1. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW: Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem. 2004 Jan 15;47(2):355-74. [PubMed:14711308 ]
  2. Almeida MR, Macedo B, Cardoso I, Alves I, Valencia G, Arsequell G, Planas A, Saraiva MJ: Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem J. 2004 Jul 15;381(Pt 2):351-6. [PubMed:15080795 ]
  3. Gales L, Macedo-Ribeiro S, Arsequell G, Valencia G, Saraiva MJ, Damas AM: Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor. Biochem J. 2005 Jun 1;388(Pt 2):615-21. [PubMed:15689188 ]
  4. Miller SR, Sekijima Y, Kelly JW: Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545-52. [PubMed:14968122 ]
  5. Tojo K, Sekijima Y, Kelly JW, Ikeda S: Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006 Dec;56(4):441-9. Epub 2006 Oct 6. [PubMed:17028027 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Davilas A, Koupparis M, Macheras P, Valsami G: In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique. J Pharm Pharmacol. 2006 Nov;58(11):1467-74. [PubMed:17132209 ]
  2. Mao H, Hajduk PJ, Craig R, Bell R, Borre T, Fesik SW: Rational design of diflunisal analogues with reduced affinity for human serum albumin. J Am Chem Soc. 2001 Oct 31;123(43):10429-35. [PubMed:11673972 ]
  3. Rehse K, Fiedler B: [Determination of the protein binding of drugs by continuous ultrafiltration. 9. Comparison of the binding of nonsteroid antirheumatics to human serum albumin and their interaction with phenprocoumon]. Arch Pharm (Weinheim). 1989 Apr;322(4):241-3. [PubMed:2751413 ]
  4. Verbeeck RK, De Schepper PJ: Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin Pharmacol Ther. 1980 May;27(5):628-35. [PubMed:7371361 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954 ]
  2. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23